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In December 2019, the novel coronavirus Coronavirus Disease 2019 (COVID-19) outbreak started in 
Wuhan, the capital of Hubei province in China.  Since then it has spread to many other regions, 
including low-income countries.(1, 2) The coronavirus was named SARS-CoV-2 (Severe Acute 
Respiratory Syndrome Coronavirus 2) and has spread to 78 countries (including many low-income 
countries), with a total of 92,818 confirmed cases globally as of 03 March 2020 (Figure 1). On 30 
January 2020, the World Health Organization (WHO) declared the outbreak a “public health 
emergency of international concern”. The first ten cases have now been reported in Africa (Algeria, 
Egypt, Morocco, Nigeria and Senegal). The spread onto the African continent is of great concern for 
multiple reasons.(3) Large and densely populated areas and townships with widespread poverty and 
high migration are the most vulnerable populations for airborne pandemics. Moreover, existing 
epidemics of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria are likely to collide 
with COVID-19 and may lead to an increased morbidity and mortality - not reported yet from affected 
countries. In addition, the wide spread of non-communicable diseases in Africa, such as chronic 
obstructive pulmonary disease (COPD), heart disease, hypertension and diabetes are known risk 
factors for severe causes of COVID-19.(2) 
 
During the past 20 years, outbreak and prevalence of severe respiratory infections have been seen as 
a major hazard to global health. In December 2019, a series of pneumonia cases of unknown aetiology 
were documented in Wuhan. High-throughput sequencing from respiratory tract samples revealed 
this novel coronavirus strain, named SARS-CoV-2.(4) In response to this outbreak, most areas in China 
have initiated policies to restrict access and traffic, as well as other measures according to the national 
prevention and control plan. China`s strong response to containing the COVID-19 epidemic was best 
practice and exemplary to the world. Back in 2003, there were 305 cases (including 5 deaths) caused 
by the outbreak of Severe Acute Respiratory Syndrome (SARS-CoV) before the Chinese government 
reported it to the WHO on 10 February 2003. However, there were only 27 cases (and no deaths) due 
to COVID-19 before it was reported to the WHO in January 2020. Since then, the global clinical and 
scientific community has established guidelines for prevention, diagnosis and management and is 
working continuously on therapeutic compounds and vaccines. 
 
As a global organization representing the cardiovascular community, with more than 200 
cardiovascular societies and foundations, the World Heart Federation is concerned that previous 
studies on other coronavirus diseases such as SARS-CoV and MERS-CoV have demonstrated a 
relationship between cardiovascular disease (cardiac disease and hypertension), diabetes and an 
increased morbidity and mortality due to coronavirus disease.(5, 6). Guan et al. reported in the New 
England Journal of Medicine on a case series of 1,099 cases with COVID-19 admitted to hospital in 
China. Patients with co-morbidities such as COPD, coronary artery and cerebrovascular disease, 
hypertension and diabetes were more likely to develop severe COVID-19 disease compared to patients 
without co-morbidities.(2) Another unpublished case series reported that about 10% of COVID-19 with 
severe disease developed acute cardiac injury with raised troponin-I/T (Bo Li et al, Clinical Research 
Cardiology, 2020, in press).  
 
The goal of this document is to update our members from low-income countries on important facts 
on COVID-19 prevention in low- and middle-income countries. 
 
Important facts 
1. The novel coronavirus 
Coronaviruses belong to a family of viruses that can cause mild disease such as a common cold, but 
also severe respiratory disease such as Middle East Respiratory Syndrome (MERS-CoV) or Severe Acute 
Respiratory Syndrome (SARS-CoV). The novel coronavirus epidemic Coronavirus Disease 2019 (COVID-
19) is caused by a coronavirus named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 
2). 
 
2. Transmission and infection 
SARS-CoV-2 is thought to have a zoonotic origin and was first isolated from patients with pneumonia 
in Wuhan, China. The spread from human-to-human is mainly an aerosol transmission through 
contaminated respiratory droplets (coughing and sneezing). In addition, respiratory droplets 
containing the virus may contaminate surfaces up to 96 hours e.g. screens of smart phones (Figure 2). 
 
3. Signs and symptoms 
Signs and symptoms of COVID-19 include flu-like symptoms such as fever, cough, fatigue, headache, 
sore throat, shortness of breath and myalgia. In rare cases nausea, vomiting and diarrhoea have 
occurred. In severe cases pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure 
and death have been reported (Figure 3). 
 
4. Prevention 
Basic recommendations to prevent COVID-19. Follow six easy rules to reduce the risk of coronavirus 
transmission. The rules are built on the principle of protecting yourself and protecting others (Figure 
4). 
 Recommendations on prevention for special populations 
People with chronic underlying disease may be at increased risk of severe COVID-19 disease and death 
(Table 1). In the largest Chinese cohort, 16% of patients developed severe disease with a mortality 
rate of 8.1%.(2) Of those patients with severe disease, 38.7% had co-morbidities. Therefore, patients 
with co-morbidities require more rigorous prevention mechanisms. For people with chronic 
respiratory disease (e.g. chronic obstructive airways disease), infectious diseases (e.g. HIV and 
tuberculosis), chronic cardiovascular disease (e.g. cardiomyopathy, previous myocardial infarction, 
rheumatic heart disease), cancer or autoimmune diseases we recommend: 
 
1. Avoid large gatherings – stay at home 
2. Keep at least 1-2 meters distance from a person with respiratory symptoms and do not stay in the 
same room with this person. 
3. Vulnerable people should consider moving to relatives in rural areas and spend their time in 
voluntary isolation, such as a small hut, receiving food supplies via a neighbour or relative, but 
without direct contact. 
4. Travel should be reduced to a minimum. Use a mask if travelling in a bus, train or plane. If masks 
are not available or affordable, cover your nose and mouth with a cloth or similar. 
 
In case SARS-CoV-2/COVID-19 begins to spread in low-income countries at high risk of airborne 
diseases, as described above, containment may not be realistic and response efforts will likely need 
to transition to various mitigation strategies, which could include isolating ill people at home, closing 
schools, universities, places of religious worship and public events which would also include attending 
funerals. 
  
Figures and Tables: 
 
Table 1: Risk factors for severe disease  
Risk factors for severe disease 
1. Age  >52 years (interquartile range 40-65) 
2. Co-morbidities 
present in 38% of patients with severe 
disease 
Hypertension 24% 
Diabetes 16% 
Coronary heart or cerebrovascular disease 8% 
Chronic obstructive pulmonary disease (COPD) 4% 
Chronic kidney disease 2% 
Cancer 2% 
3. Additional risk factor 
unique for low-income countries 
HIV 
Tuberculosis 
Chronic obstructive pulmonary disease (COPD) 
Rheumatic heart disease (RHD) 
Cardiomyopathies 
The table outlines risk factors for severe COVID-19 disease and co-morbidities from China (from Guan 
et al. Clinical characteristics of coronavirus disease 2019 in China, NEJM, 2020) and low-income 
settings with a focus on Sub-Saharan Africa. 
 
Table 2: Important resources and information 
World Health Organization www.who.int/health-topics/coronavirus 
 
European Centre for Disease Prevention and Control 
 
www.ecdc.europa.eu/en/coronavirus 
US Centers for Disease Control and Prevention www.cdc.gov/coronavirus/2019-nCoV 
 
Uptodate www.uptodate.com/contents/coronavirus-
disease-2019-covid-19 
 
 
Figure 1: Global map of SARS-CoV-2/COVID-19 epidemic by region 
  
 
 
 
Figure 2: Transmission and infection  
 
 
 
 
 
 Figure 3: Signs and symptoms 
 
 
 
 
Figure 4 :Prevention 
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